Hims & Hers Health, Inc. (HIMS)
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
HIMS stock spikes over 40%; Time to buy?
Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform.⚈ The move positions Hims & Hers to capitalize on booming demand for weight-loss medications.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally restricted from making cheaper, unapproved versions of Wegovy, with rare exceptions.
Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put options offers a better risk/reward. Selling the August, $18-strike put options yields 27.7% annualized, providing a robust yield, and a potentially stronger entry point at a more attractive valuation.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14% change from the preceding trading day.
The FDA has posted a warning about generic forms of a popular hair-loss medication often sold by major telehealth companies including Hims, Keeps and Ro
Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Top Pick For The Next Decade
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
Investment strategist picks 3 ‘new age' healthcare stocks to buy
Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
Bull of the Day: Hims & Hers Health (HIMS)
Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.
